Testing Acolbifene vs Low Dose Tamoxifen to Prevent Breast Cancer
Official Title
Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer
Purpose
This study wants to see if two medicines, acolbifene or a small dose of tamoxifen, can lower the chance of getting breast cancer in women who are at high risk before menopause.
Acolbifene and tamoxifen work by blocking estrogen, a hormone that can help cancer cells grow. By blocking estrogen, these medicines may lower the chance of breast cancer in women at high risk. The study lasts between 6 and 8 months.
If this study works, it could give us new ways to help prevent breast cancer.
Could this study be right for you?
- Pre-menopausal
- At increased risk of breast cancer, due to genetic mutation, family history, prior DCIS, LCIS, or atypical hyperplasia
- Seen in Stefanie Spielman Comprehensive Breast Cancer Center in Columbus, OH